dafa登录官网|欢迎莅临!

Providing innovative and affordable medicines
for all patients

Supported by our strong talent base and our fully integrated R&D platform, we have developed, and continued to expand a comprehensive product pipeline of multiple late-stage biologics candidates and bio-innovative drugs, with significant potential for a variety of PD-1/PD-L1 based immuno-oncology combination therapies.


Until now, we have completed IND/CTA filings of 13 products and 2 combination therapies with 23 indications and obtained 29 successful IND/CTA approvals (19 approvals from mainland China; 3 from the United States; 3 from Taiwan, China; each 1 from the European Union, Ukraine, Philippines and Australia). HLX01 (rituximab injection), our first product, has been granted approval by the NMPA as the first approved biosimilar in China. Moreover, HLX03 has received a New Drug Application (NDA) acceptance from NMPA.

Intellectual Property
Relevant
Products
Patent Name Patent Holder Patent Number Jurisdiction of
Registration
Application
Date
Expiry Date Type
Platform Technology Kit for detecting DNA residues of CHO cell and using method thereof Henlius ZL201110066745.4 Chinese mainland 2011-03-18 2031-03-18 Invention
Platform Technology Method for detecting DNA content of CHO cells by probe Henlius ZL201110099204.1 Chinese mainland 2011-04-20 2031-04-20 Invention
Platform Technology Eukaryotic expression vector and system for producing recombinant protein by using CHO cells Henlius ZL201210211812.1 Chinese mainland 2012-06-25 2032-06-25 Invention
HLX07

Anti-epidermal growth factor receptor (EGFR) antibodies

Henlius ZL201580029644.6
HK1252789
J/4492
TWI689520
US10584171
AU2015266664
JP6691872
EP3148581
EP3613433
KR102366644
US11261255

Chinese mainland

Hong Kong China

Macao China

Taiwan China

The United States

Australia

Japan

UK, GER, FR, ITA, ESP

UK, GER, FR, ITA, ESP

Korea

The United States






2015-05-29





2035-05-29




2035-12-11
Invention
HLX10

Anti-programmed cell death protein 1 monoclonal antibody injection



Anti-PD-1 antibodies

Henlius ZL202010008058.6
HK40018285

ZA201901865
US11028173
RU2752832
JP7072576
ZL201780056868.5
TWI772326
KR102391338
IDP000083833

Chinese mainland

Hong Kong China


The United States

South Africa

Russia

Japan

Chinese mainland

Taiwan China

Korea

Indonesia

2020-01-06



2017-09-09
2040-01-06



2037-09-08


2037-09-09
2037-09-09
2037-09-15
2037-09-09
2037-09-09
Invention
HLX53 AntiI-TIGIT antibodies and methods of use Henlius ZL202010024565.9
HK40013828

Chinese mainland

Hong Kong China

2020-01-10 2040-01-10 Invention
Platform Technology Online system for monitoring yield and quality of target protein  Henlius ZL202020160862.1 Chinese mainland 2020-02-11 2030-02-10 Utility Model
Platform Technology Online quantitative detection system for target protein Henlius ZL202020432845.9 Chinese mainland 2020-03-30 2030-03-29 Utility Model
Publications
XML 地图 | Sitemap 地图